HPV-DNA integration and carcinogenesis: Putative roles for inflammation and oxidative stress

Future Virology

Volumn 6, Issue 1, 2011, Pages 45-57

  Williams, Vonetta M ^a   Filippova, Maria ^a   Soto, Ubaldo ^a   Duerksen Hughes, Penelope J ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bacterial co infection; cervical cancer; DNA damage; HPV; inflammation; integration; oropharyngeal cancer; oxidative stress; papillomavirus; viral

Indexed keywords

REACTIVE OXYGEN METABOLITE; VIRUS DNA; WART VIRUS VACCINE;

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHROMATIN; DNA INTEGRATION; DNA STRAND BREAKAGE; GENITAL HERPES; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRECANCER; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; WART VIRUS;

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 78650675388     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.73     Document Type: Review

References (163)

1. Flores E, Lambert P: Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J. Virol. 71(10), 7167-7179 (1997).
2. Calleja-Macias IE, Kalantari M, Allan B et al.: Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b. J. Virol. 79(10), 6565-6569 (2005).
3. Ault KA: Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol. Oncol 107(2 Suppl. 1), S31-S33 (2007).
4. Guccione E, Pim D, Banks L: HPV-18 E6*I modulates HPV-18 full-length E6 functions in a cell cycle dependent manner. Int. J. Cancer 110(6), 928-933 (2004).
5. Weaver BA: Epidemiology and natural history of genital human papillomavirus infection. J. Am. Osteopath. Assoc. 106(Suppl. 1), S2-S8 (2006).
6. Walboomers JMM, Jacobs MV, Manos MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999).
7. Wei L, Gravitt PE, Song H, Maldonado AM, Ozbun MA: Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res. 69(11), 4878-4884 (2009).
8. Zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184(1), 9-13 (1991).
9. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Pre. 14(5), 1157-1164 (2005).
10. Liu Y, Tergaonkar V, Krishna S, Androphy EJ: Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor a correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274(35), 24819-24827 (1999).
11. Lowy D, Kirnbauer R, Schiller J: Genital human papillomavirus infection. PNAS 91(7), 2436-2440 (1994).
12. Bedell MA, Hudson JB, Golub TR et al.: Amplifcation of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 65(5), 2254-2260 (1991).
13. Stanley MA, Browne HM, Appleby M, Minson AC: Properties of a non-tumorigenic human cervical keratinocyte cell line. Int. J. Cancer 43(4), 672-676 (1989).
14. Pett M, Coleman N: Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J. Pathol. 212(4), 356-367 (2007).
15. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT: Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9(19), 2335-2349 (1995).
16. Higgins GD, Uzelin DM, Phillips GE, Mcevoy P, Marin R, Burrell CJ: Transcription patterns of human papillomavirus type 16 in genital intraepithelial neoplasia: evidence for promoter usage within the E7 open reading frame during epithelial differentiation. J. Gen. Virol. 73(8), 2047-2057 (1992).
17. Medzhitov R, Janeway CA Jr: Decoding the patterns of self and nonself by the innate immune system. Science 296(5566), 298-300 (2002).
18. Hasan UA, Bates E, Takeshita F et al.: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178(5), 3186-3197 (2007).
19. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD: Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-kB-responsive genes in cervical keratinocytes. J. Virol. 75(9), 4283-4296 (2001).
20. Stanley M: Immune responses to human papillomavirus. Vaccine 24(Suppl. 1), S16-S22 (2006).
21. Coleman N, Birley HD, Renton AM et al.: Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102(6), 768-774 (1994).
22. Boccardo E, Lepique AP, Villa LL: The role of infammation in HPV carcinogenesis. Carcinogenesis 31(11), 1905-1912 (2010).
23. Dunne EF, Unger ER, Sternberg M et al.: Prevalence of HPV infection among females in the united states. JAMA 297(8), 813-819 (2007).
24. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl. 3), S11-S25 (2006).
25. Klozar J, Tachezy R, Rotnáglová E, Kolabová E, Saláková M, Hamíková E: Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects. WMW Wiener Medizinische Wochenschrift 160(11), 305-309 (2010).
26. Watson M, Saraiya M, Wu X: Update of HPV-associated female genital cancers in the united states, 1999-2004. J. Women's Health (Larchmt) 18(11), 1731-1738 (2009).
27. Frisch M, Fenger C, Van Den Brule AJC et al.: Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res. 59(3), 753-757 (1999).
28. Daling JR, Madeleine MM, Johnson LG et al.: Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101(2), 270-280 (2004).
29. Hopman A, Theelen W, Hommelberg P et al.: Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J. Pathol. 210(4), 412-419 (2006).
30. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ: HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208(2), 152-164 (2006).
31. Pirami L, Giachè V, Becciolini A: Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J. Clin. Pathol. 50, 600-604 (1997).
32. Cullen AP, Reid R, Campion M, Lorincz AT: Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Virol. 65(2), 606-612 (1991).
33. Vinokurova S, Wentzensen N, Kraus I et al.: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68(1), 307-313 (2008).
34. Gray E, Pett MR, Ward D et al.: In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res. 70(10), 4081-4091 (2010).
35. Daniel B, Rangarajan A, Mukherjee G, Vallikad E, Krishna S: The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J. Gen. Virol. 78(5), 1095-1101 (1997).
36. Vinokurova S, Wentzensen N, Kraus I et al.: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68(1), 307-313 (2008).
37. Schwarz E, Freese UK, Gissmann L et al.: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314(6006), 111-114 (1985).
38. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM: Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J. Clin. Microbiol. 44(5), 1755-1762 (2006).
39. Briolat J, Dalstein V, Saunier M et al.: HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of cin. Int. J. Cancer 121(10), 2198-2204 (2007).
40. Hudelist G, Manavi M, Pischinger KID et al.: Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol. Oncol. 92(3), 873-880 (2004).
41. Peter M, Stransky N, Couturier J et al.: Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J. Pathol. 221(3), 320-330 (2010).
42. Wentzensen N, Vinokurova S, Doeberitz MVK: Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64(11), 3878-3884 (2004).
43. Hiraku Y: Formation of 8-nitroguanine, a nitrative DNA lesion, in infammation-related carcinogenesis and its signifcance. Environ. Health Prev. Med. 15(2), 63-72 (2010).
44. Zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92(9), 690-698 (2000).
45. Munger K, Baldwin A, Edwards KM et al.: Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78(21), 11451-11460 (2004).
46. Jeon S, Lambert PF: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc. Natl Acad. Sci. USA 92(5), 1654-1658 (1995).
47. Badaracco G, Venuti A, Sedati A, Marcante ML: HPV16 and HPV18 in genital tumors: signifcantly different levels of viral integration and correlation to tumor invasiveness. J. Med. Virol. 67(4), 574-582 (2002).
48. Romanczuk H, Howley PM: Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity Proc. Natl Acad. Sci. USA 89(7), 3159-3163 (1992).
49. Popescu NC, Dipaolo JA: Integration of human papillomavirus 16 DNA and genomic rearrangements in immortalized human keratinocyte lines. Cancer Res. 50(4), 1316-1323 (1990).
50. Ferber MJ, Montoya DP, Yu C et al.: Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22(24), 3813-3820 (2003).
51. Winder DM, Pett MR, Foster N et al.: An increase in DNA double-strand breaks, induced by KU70 depletion, is associated with human papillomavirus 16 episome loss and De novo viral integration events. J. Pathol. 213(1), 27-34 (2007).
52. Someya M, Sakata K-I, Matsumoto Y et al.: The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis 27(1), 117-122 (2006).
53. Winder D, Pett M, Foster N et al.: An increase in DNA double-strand breaks, induced by KU70 depletion, is associated with human papillomavirus 16 episome loss and De novo viral integration events. J. Pathol. 213(1), 27-34 (2007).
54. Dandri M, Burda MR, Bürkle A et al.: Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 35(1), 217-223 (2002).
55. Kawanishi S, Hiraku Y, Pinlaor S, Ma N: Oxidative and nitrative DNA damage in animals and patients with infammatory diseases in relation to infammation-related carcinogenesis. Biol. Chem. 387(4), 365-372 (2006).
56. Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G: Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine 26(Suppl. 11), L16-L36 (2008).
57. Munoz N, Franceschi S, Bosetti C et al.: Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359(9312), 1093-1101 (2002).
58. Plummer M, Herrero R, Franceschi S et al.: Smoking and cervical cancer: pooled ana lysis of the IARC multi-centric case-control study. Cancer Causes Control 14(9), 805-814 (2003).
59. Deacon JM, Evans CD, Yule R et al.: Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the manchester cohort. Br. J. Cancer 83(11), 1565-1572 (2000).
60. Tollefson AK, Oberley-Deegan RE, Butterfeld KT et al.: Endogenous enzymes (NOX and ECSOD) regulate smoke-induced oxidative stress. Free Radic. Biol. Med. DOI: 10.1016/j.freeradbiomed.2010.09.022 (2010) (Epub ahead of print).
61. Castellsague X, Munoz N: Chapter 3: cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J. Natl Cancer Inst. Monogr. (31), 20-28 (2003).
62. Vaccarella S, Herrero R, Dai M et al.: Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled ana lysis of the IARC HPV prevalence surveys. Cancer Epidemiol. Biomarkers Prev. 15(11), 2148-2153 (2006).
63. Moreno V, Bosch FX, Muñoz N et al.: Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359 (9312), 1085-1092 (2002).
64. Appleby P, Beral V, Berrington de González A; International Collaboration of Epidemiological Studies of Cervical Cancer: Cervical cancer and hormonal contraceptives: collaborative reana lysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599), 1609-1621 (2007).
65. Smith JS, Green J, De Gonzalez AB et al.: Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361(9364), 1159-1167 (2003).
66. Castle PE, Giuliano AR: Chapter 4: genital tract infections, cervical infammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J. Natl Cancer Inst. Monogr. 2003(31), 29-34 (2003).
67. Castle PE, Hillier SL, Rabe LK et al.: An association of cervical infammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol. Biomarkers Prev. 10(10), 1021-1027 (2001).
68. Kulkarni S, Rader JS, Zhang F et al.: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7(2), 429-434 (2001).
69. Kim GE, Kim YB, Cho NH et al.: Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix. Clin. Cancer Res. 10(4), 1366-1374 (2004).
70. Saldivar JS, Lopez D, Feldman RA et al.: COX-2 overexpression as a biomarker of early cervical carcinogenesis: a pilot study. Gynecol. Oncol. 107(1 Suppl. 1), S155-S162 (2007).
71. Hammes LS, Tekmal RR, Naud P et al.: Up-regulation of VEGF, c-FMS and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol. Oncol. 110(3), 445-451 (2008).
72. Pikarsky E, Porat RM, Stein I et al.: NF-kB functions as a tumour promoter in infammation-associated cancer. Nature 431(7007), 461-466 (2004).
73. Ravi R, Bedi A: NF-kB in cancer - a friend turned foe. Drug Resist. Updat. 7(1), 53-67 (2004).
74. Rasmussen SJ, Eckmann L, Quayle AJ et al.: Secretion of proinfammatory cytokines by epithelial cells in response to chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J. Clin. Invest. 99(1), 77-87 (1997). (Pubitemid 27058297)
75. Finan RR, Musharrafeh U, Almawi WY: Detection of chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. Clin. Microbiol. Infect. 12(9), 927-930 (2006).
76. Hawes SE, Kiviat NB: Are genital infections and infammation cofactors in the pathogenesis of invasive cervical cancer? J. Natl Cancer Inst. 94(21), 1592-1593 (2002).
77. Szostek S, Zawilinska B, Kopec J, Kosz-Vnenchak M: Herpesviruses as possible cofactors in HPV-16-related oncogenesis. Acta Biochim. Pol. 56(2), 337-342 (2009).
78. Paba P, Bonifacio D, Di Bonito L et al.: Co-expression of HSV2 and chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways. Intervirology 51(4), 230-234 (2008).
79. Schwebke JR, Zajackowski ME. Effect of concurrent lower genital tract infections on cervical cancer screening. Genitourin. Med. 73(5), 383-386 (1997).
80. Nasca MR, Innocenzi D, Micali G: Association of penile lichen sclerosus and oncogenic human papillomavirus infection. Int. J. Dermatol. 45(6), 681-683 (2006).
81. Barbagli G, Palminteri E, Mirri F, Guazzoni G, Turini D, Lazzeri M: Penile carcinoma in patients with genital lichen sclerosus: a multicenter survey. J. Urol. 175(4), 1359-1363 (2006).
82. Bartsch H, Nair J: Chronic infammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbeck's Arch. Surg. 391(5), 499-510 (2006).
83. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G: Infammation and cancer: how hot is the link? Biochem. Pharmacol. 72(11), 1605-1621 (2006).
84. Lu H, Ouyang W, Huang C: Infammation, a key event in cancer development. Mol. Cancer Res. 4(4), 221-233 (2006).
85. Coussens LM, Werb Z: Infammation and cancer. Nature 420(6917), 860-867 (2002).
86. Carlson JA, Ambros R, Malfetano J et al.: Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic infammation and sclerosis in the development of neoplasia. Hum. Pathol. 29(9), 932-948 (1998).
87. Di Bisceglie AM: Hepatitis C and hepatocellular carcinoma. Hepatology 26(S3), 34S-38S (1997).
88. Brechot C, Kremsdorf D, Soussan P et al.: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol. Biol. 58(4), 278-287 (2010).
89. Khan G: Epstein-Barr virus, cytokines, and infammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp. Hematol. 34(4), 399-406 (2006).
90. Moore MM, Chua W, Charles KA, Clarke SJ: Infammation and cancer: causes and consequences. Clin. Pharmacol. Ther. 87(4), 504-508 (2010).
91. Balkwill F, Mantovani A: Infammation and cancer: back to Virchow? Lancet 357(9255), 539-545 (2001).
92. Peebles KA, Lee JM, Mao JT et al.: Infammation and lung carcinogenesis: applying fndings in prevention and treatment. Expert Rev. Anticancer Ther. 7(10), 1405-1421 (2007).
93. Jezek P, Hlavata L: Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int. J. Biochem. Cell Biol. 37(12), 2478-2503 (2005).
94. Nathan C: Specifcity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 111(6), 769-778 (2003).
95. Krüncke KD: Nitrosative stress and transcription. Biol. Chem. 384(10-11), 1365-1377 (2005).
96. Chang M-L, Chen J-C, Chang M-Y et al.: Acute expression of hepatitis C core protein in adult mouse liver: mitochondrial stress and apoptosis. Scand. J. Gastroenterol. 43(6), 747-755 (2008).
97. Bartsch H, Nair J: Chronic infammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 391(5), 499-510 (2006).
98. Tamir S, Tannenbaum SR: The role of nitric oxide (NO·) in the carcinogenic process. Biochim. Biophys. Acta. 1288(2), F31-F36 (1996).
99. Baron JA, Sandler RS: Nonsteroidal anti-infammatory drugs and cancer prevention. Ann. Rev. Med. 51(1), 511-523 (2003).
100. Prescott SM, Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta 1470(2), M69-M78 (2000).
101. Roede JR, Jones DP: Reactive species and mitochondrial dysfunction: mechanistic signifcance of 4-hydroxynonenal. Environ. Mol. Mutagen. 51(5), 380-390 (2010).
102. Disilvestro RA: Infuence of copper intake and infammation on rat serum superoxide dismutase activity levels. J. Nutr. 118(4), 474-479 (1988).
103. Srivastava S, Natu SM, Gupta A et al.: Lipid peroxidation and antioxidants in different stages of cervical cancer: prognostic signifcance. Indian J. Cancer 46, 297-302 (2009).
104. Manju V, Kalaivani Sailaja J, Nalini N: Circulating lipid peroxidation and antioxidant status in cervical cancer patients: a case-control study. Clin. Biochem. 35(8), 621-625 (2002).
105. Looi ML, Mohd Dali AZ, Md Ali SA, Wan Ngah WZ, Mohd Yusof YA: Oxidative damage and antioxidant status in patients with cervical intraepithelial neoplasia and carcinoma of the cervix. Eur. J. Cancer Prev. 17(6), 555-560 (2008).
106. Valko M, Morris H, Cronin MTD: Metals, toxicity and oxidative stress. Curr. Med. Chem. 12, 1161-1208 (2005).
107. Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 21(3), 361-370 (2000).
108. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 160(1), 1-40 (2006).
109. Inoue S, Kawanishi S: Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. FEBS Lett. 371(1), 86-88 (1995).
110. Yermilov V, Rubio J, Becchi M, Friesen MD, Pignatelli B, Ohshima H: Formation of 8-nitroguanine by the reaction of guanine with peroxynitrite in vitro. Carcinogenesis 16(9), 2045-2050 (1995).
111. Akaike T, Okamoto S, Sawa T et al.: 8-nitroguanosine formation in viral pneumonia and its implication for pathogenesis. Proc. Natl Acad. Sci. USA 100(2), 685-690 (2003).
112. Kawanishi S, Hiraku Y, Oikawa S: Mechanism of guanine-specifc DNA damage by oxidative stress and its role in carcinogenesis and aging. Mutat. Res. 488(1), 65-76 (2001).
113. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39(1), 44-84 (2007).
114. Sgambato A, Zannoni GF, Faraglia B et al.: Decreased expression of the CDK inhibitor p27KIP1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecol. Oncol. 92(3), 776-783 (2004).
115. Sawa T, Akaike T, Ichimori K et al.: Superoxide generation mediated by 8-nitroguanosine, a highly redox-active nucleic acid derivative. Biochem. Biophys. Res. Commun. 311(2), 300-306 (2003).
116. Suzuki N, Yasui M, Geacintov NE, Shafrovich V, Shibutani S: Miscoding events during DNA synthesis past the nitration-damaged base 8- nitroguanineâ. Biochemistry 44(25), 9238-9245 (2005).
117. Takahashi T, Nau M, Chiba I et al.: P53: a frequent target for genetic abnormalities in lung cancer. Science 246(4929), 491-494 (1989).
118. Tamura G, Nishizuka S, Maesawa C et al.: Mutations in mitochondrial control region DNA in gastric tumours of Japanese patients. Eur. J. Cancer 35(2), 316-319 (1999).
119. Horton TM, Petros JA, Heddi A et al.: Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer 15(2), 95-101 (1996).
120. Beckman KB, Ames BN: Oxidative decay of DNA. J. Biol. Chem. 272(32), 19633-19636 (1997).
121. Berlett BS, Stadtman ER: Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272(33), 20313-20316 (1997).
122. Subrahmanyam V V, McGirr LG, O'Brien PJ: Glutathione oxidation during peroxidase catalysed drug metabolism. Chem. Biol Interact. 61(1), 45-59 (1987).
123. Uchida K: 4-hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42(4), 318-343 (2003)
124. Blair IA: Lipid hydroperoxide-mediated DNA damage. Exp. Gerontol. 36(9), 1473-1481 (2001).
125. Nair J, Barbin A, Velic I, Bartsch H: Etheno DNA-base adducts from endogenous reactive species. Mutat. Res. 424(1-2), 59-69 (1999).
126. Ruef J, Rao GN, Li F et al.: Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal. Circulation 97(11), 1071-1078 (1998).
127. Cheng J-Z, Singhal SS, Saini M et al.: Effects of MGST a4 transfection on 4-hydroxynonenal-mediated apoptosis and differentiation of K562 human erythroleukemia cells. Arch. Biochem. Biophys. 372(1), 29-36 (1999).
128. Hu W, Feng Z, Eveleigh J et al.: The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 23(11), 1781-1789 (2002).
129. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO: Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24(8), 792-799 (2002).
130. Kumagai T, Kawamoto Y, Nakamura Y et al.: 4-hydroxy-2-nonenal, the end product of lipid peroxidation, is a specifc inducer of cyclooxygenase-2 gene expression. Biochem. Biophys. Res. Commun. 273(2), 437-441 (2000).
131. Song SH, Lee JK, Oh MJ, Hur JY, Park YK, Saw HS: Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix. Int. J. Gynecol. Cancer 16(4), 1608-1613 (2006).
132. Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12(2), 186-192 (1993).
133. Tamim H, Finan RR, Sharida HE, Rashid M, Almawi WY: Cervicovaginal coinfections with human papillomavirus and chlamydia trachomatis. Diagn. Microbiol. Infect. Dis. 43(4), 277-281 (2002).
134. Münger K, Basile JR, Duensing S et al.: Biological activities and molecular targets of the human papillomavirus e7 oncoprotein. Oncogene 20, 7888-7898 (2001).
135. Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20, 7874-7887 (2001).
136. Duensing S, Münger K: The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 62(23), 7075-7082 (2002).
137. Zur Hausen H: Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. 9(6), 405-411 (1999).
138. von Knebel Doeberitz M: New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur. J. Cancer 38(17), 2229-2242 (2002).
139. Patel D, Incassati A, Wang N, Mccance DJ: Human papillomavirus type 16 E6 and E7 cause polyploidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Res. 64(4), 1299-1306 (2004).
140. Scheffner M, Münger K, Byrne JC, Howley PM: The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl Acad. Sci. USA 88(13), 5523-5527 (1991).
141. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6), 1129-1136 (1990).
142. Werness B, Levine A, Howley P: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248(4951), 76-79 (1990).
143. Huibregtse JM, Scheffner M, Howley PM: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus type-16 or type-18. Embo J. 10(13), 4129-4135 (1991).
144. Huibregtse JM, Scheffner M, Howley PM: Cloning and expression of the CDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell Biol. 13(2), 775-784 (1993).
145. Tungteakkhun SS, Duerksen-Hughes PJ: Cellular binding partners of the human papillomavirus E6 protein. Arch. Virol. 153(3), 397-408 (2008).
146. Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20(54), 7874-7887 (2001).
147. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J. 8(13), 4099-4105 (1989).
148. Dyson N, Guida P, Munger K, Harlow E: Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66(12), 6893-6902 (1992).
149. Mclaughlin-Drubin ME, Münger K: The human papillomavirus E7 oncoprotein. Virology 384(2), 335-344 (2009).
150. Pett MR, Alazawi WOF, Roberts I et al.: Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 64(4), 1359-1368 (2004).
151. Tsai WL, Chung RT: Viral hepatocarcinogenesis. Oncogene 29(16), 2309-2324 (2010).
152. Dandri M, Burda MR, Bürkle A et al.: Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology 35(1), 217-223 (2002).
153. Koike K: Hepatitis B virus X gene is implicated in liver carcinogenesis. Cancer Lett. 286(1), 60-68 (2009).
154. Matsumoto K, Oki A, Furuta R et al.: Tobacco smoking and regression of low-grade cervical abnormalities. Cancer Sci. 101(9), 2065-2073 (2010).
155. Ngo MA, Sinitsyna NN, Qin Q, Rice RH: Oxygen-dependent differentiation of human keratinocytes. J. Invest. Dermatol. 127(2), 354-361 (2006).
156. Sandler AB, Dubinett SM: COX-2 inhibition and lung cancer. Semin. Oncol. 31(Suppl. 7), 45-52 (2004).
157. Arun B, Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol. 31(Suppl. 7), 22-29 (2004).
158. Reddy BS, Hirose Y, Lubet R et al.: Chemoprevention of colon cancer by specifc cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60(2), 293-297 (2000).
159. Madhusudan S, Muthuramalingam SR, Braybrooke JP et al.: Study of etanercept, a tumor necrosis factor-a inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23(25), 5950-5959 (2005).
160. Harrison ML, Obermueller E, Maisey NR et al.: Tumor necrosis factor {a} as a new target for renal cell carcinoma: Two sequential Phase II trials of infiximab at standard and high dose. J. Clin. Oncol. 25(29), 4542-4549 (2007).
161. Brown ER, Charles KA, Hoare SA et al.: A clinical study assessing the tolerability and biological effects of infiximab, a TNF-a inhibitor, in patients with advanced cancer. Ann. Oncol. 19(7), 1340-1346 (2008).
162. Steinbach G, Lynch PM, Phillips RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342(26), 1946-1952 (2000).
163. Bertagnolli MM, Eagle CJ, Zauber AG et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355(9), 873-884 (2006).